Skip to content
Elizabeth Holmes- Case Archive
personpersonMark PandoriMark PandoriPathologist and former Theranos clinical laboratory director.← All People
MentionedTheranos

Mark Pandori

Pathologist and former Theranos clinical laboratory director.

MentionedFederal Criminal Trial
10 proceedings·10 mentions

About

Trial testimony placed Mark Pandori in Theranos's laboratory leadership as clinical laboratory director, alongside medical director Adam Rosendorff. Erika Cheung described reporting quality-control information to Pandori and communicating with him about patient testing, Edison-device errors, failed quality controls, proficiency testing, and laboratory procedures.

Later testimony and documents connected Pandori to a proposed alternative-assessment process, comparison studies, and a laboratory spot check. Rosendorff disputed whether the alternative-assessment process had been formally implemented, and a June 2014 email proposed an operational role for Ramesh Balwani after Pandori's departure.

Trial Record (10)

FederalFederal Criminal TrialAug 31, 2021 – Jan 3, 2022

Trial testimony identified Mark Pandori as Theranos's clinical laboratory director and connected him to laboratory supervision, quality control, proficiency testing, alternative assessment, and test-comparison work.

Day 7

CrossErika Cheung — CrossErika CheungLance A. WadeMentioned

Summary

Defense counsel emphasized Theranos's trained laboratory teams, formal validation reports, multiple approvals, and written operating procedures while narrowing Cheung's personal expertise. Cheung agreed that QC preceded patient testing but maintained that validation was sometimes compressed, written procedures differed from practice, and frequent reader failures required extensive recalibration.

Mentioned in this proceeding.

Day 8

CrossErika Cheung — CrossErika CheungLance A. WadeMentioned

Summary

Defense counsel used laboratory procedures, email chains, workflow improvements, and a sample-volume patent to emphasize Theranos's monitoring and remediation systems and to narrow Cheung's expertise. Cheung nevertheless maintained that the vitamin D SOP was not followed, confirmed that hepatitis C was not run on Edison after her concerns, and described Edison as a one-patient, one-test device.

Mentioned in this proceeding.

Day 11

Day 12

Day 13

CrossAdam Rosendorff — CrossAdam RosendorffLance A. WadeMentioned

Summary

Defense counsel challenged Adam Rosendorff with inspection records, compliance emails, signed Edison validation reports, quality-system data, and proficiency-testing records. Rosendorff acknowledged inspection cooperation, assay approvals, and predicate-device proficiency testing while maintaining that later Edison performance, incident management, and alternative testing remained deficient.

Mentioned in this proceeding.

Day 14

CrossAdam Rosendorff — CrossAdam RosendorffLance A. WadeMentioned

Summary

Defense counsel challenged Adam Rosendorff with AAP policies, laboratory emails, physician-call records, and meeting calendars. Rosendorff accepted substantial laboratory-director responsibility but maintained that proficiency-testing implementation and data access were incomplete and that management sometimes exceeded its qualifications.

Mentioned in this proceeding.

Day 16

RedirectAdam Rosendorff — RedirectAdam RosendorffJohn C. Bostic1highlightMentioned

Summary

Adam Rosendorff testified that Theranos-specific and fingerstick testing presented recurring reliability problems, clarified the limits of the company's proficiency testing, and described a gap between his regulatory responsibility and management's practical control of laboratory operations.

Mentioned in this proceeding.

Highlights (1)

rulingRosendorff defended a February 2014 Edison spot check as a useful clinical-laboratory evaluation despite its not being a formal AAP procedure. When the prosecution asked what Mark Pandori had said about leaving Theranos, the court sustained the defense's hearsay objection and sustained it again after the prosecution invoked an exception.Open in transcript →
RecrossAdam Rosendorff — RecrossAdam RosendorffLance A. WadeMentioned

Summary

Defense counsel used emails and prior testimony to challenge Adam Rosendorff on laboratory authority, HCG implementation, launch scope, and complaint frequency. Rosendorff made several concessions but preserved qualifications about operational control, quality-control failures, and limited recollection.

Mentioned in this proceeding.